Biologics Are Ray Of Light In Dim Outlook For FDA’s 2008 Approval Totals
This article was originally published in The Pink Sheet Daily
Executive Summary
At the half-year mark, FDA had approved eight novel BLAs – more than in all of 2007.
You may also be interested in...
ZymoGenetics Experiences a Biotech Disconnect
It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.
Turning Back the Clock: Drug Approvals Hit 25 Year Low
You have to go back to 1983 to find a year as bad as 2007 for R&D output. It was a terrible year by any measure. The key question for industry: does it need to learn to subsist on a trickle of new drugs coming to market each year, or is the current drought in fact a sign of a transition to a new, more innovative R&D model? The sparse class of 2007 does offer some glimmers of hope.
Minimal Residual Disease Gains Max US FDA AdComm Support For Myeloma Trials
The US FDA’s Oncologic Drugs Advisory Committee unanimously agreed that accelerated approvals should be enabled by multiple myeloma trials using MRD as a surrogate endpoint.